Understanding the Course of SARS-CoV-2 Infection (Sakmar)

One of the puzzles of this virus is the unknown incubation period of the virus, with the classic story being development of escalating symptoms 4-7 days after exposure, but some patients having potentially long incubation periods during which they may be infectious and expose many people. In the latter case, waiting until classic symptoms appear […]

Repurposing Drugs (Rice)

In the near term, virologist Charlie Rice, who won the Lasker Award for developing the methods that enabled high throughput screens that led to the cure for hepatitis C, is developing related high-throughput assays to screen for new inhibitors of SARS-CoV-2 replication and also developing coronavirus replicon systems with convenient reporters that can be used […]

Rapid Screening Tests for SARS-CoV-2 (Darnell)

A major clinical issue has been the failure to deploy rapid, reliable and highly scalable methods to diagnose SARS-CoV-2 infection. Physician-scientist Bob Darnell is working on new methods to rapidly diagnose infection and develop a model by which patients could potentially do simple at-home sample collection that can be sent in for testing. The rapid […]

Optimization of Antibodies (Ravetch)

Antibodies are made of a highly variable ?front end? by which they bind very specific targets, and a “back end” Fc portion that binds to specific immune cells via receptors that are specific for Fc. Immunologist Jeffrey Ravetch discovered that modifying the Fc portion of antibodies can drastically change the effects antibodies have when they […]

Novel Adenylyl Cyclase 1 Inhibitors for Treatment of Chronic Pain

Technology Readiness Level: Process Validation in Lab Researchers at Purdue University have synthesized compounds to treat chronic pain by inhibiting adenylyl cyclase 1 (AC1), an effector of the opioid receptor. Opioids are currently the most widely used drugs to treat chronic pain, but their use is commonly associated with addiction and dependency. A contributing factor […]

New Targets for Therapy (Rice)

Charlie Rice is coupling this effort with doing highly innovative work using CRISPR technology to knock out genes in the human genome to screen for those whose loss prevents infection by SARS-CoV-2. He has already identified a gene called LYE6E as a gene that?s essential for entry of the virus into cells. Charlie?s lab will […]

New Targets for Therapy (Casanova)

A parallel approach to Charlie Rice’s is being taken by Jean-Laurent Casanova, a superb human geneticist who has identified many genes whose mutation causes unusual susceptibility to infectious agents such as the bacterium that causes tuberculosis or the influenza virus. He is now collecting DNA samples from patients from around the world who have had […]

New Animal Models for Testing (Victora)

Animal models to support pre-clinical testing of inhibitors of SARS-CoV-2 are not very good and not generally available. The SARS-CoV-2 virus enters cells by its ?S? protein attaching to the cell surface protein ACE2. Immunologist Gabriel Victora will use his expertise in application of CRISPR technology to make the mouse ACE2 receptor identical to its […]

Nanobodies for Prevention and Treatment of COVID-19 (Rout, Chait)

Nanobodies are a novel class of very small antibody-like molecules found in the blood of camels and related species. Because of their small size and simplicity, they can be manufactured at low cost, have high stability, low immunogenicity, and can be of very high affinity, making them excellent candidates for therapeutics and diagnostics. Because of […]

KL-US9061474 – Colorless Polyimides

High clarity, colorless: Optically transparent material offers light-transmission properties that are greater than 89% at 550 nm. High-temperature stability: The material’s glass transition temperature is >300°C, and its coefficient of thermal expansion (CTE) is